Key Trials Evaluating Nanoplastic Exposure and Cardiovascular Disease
The landmark trial establishing the association between nanoplastics and cardiovascular events is the prospective multicenter observational study by Marfella et al. (2024), which demonstrated that patients with microplastics and nanoplastics (MNPs) detected in carotid artery plaques had a 4.5-fold increased risk of myocardial infarction, stroke, or death compared to those without detectable MNPs 1.
The Pivotal Human Evidence
The Marfella Study (2024) - The Definitive Trial
This prospective study enrolled 304 patients undergoing carotid endarterectomy for asymptomatic carotid artery disease 1. The study design was methodologically rigorous:
- Detection methods: Pyrolysis-gas chromatography-mass spectrometry, stable isotope analysis, and electron microscopy
- Follow-up: Mean 33.7 ± 6.9 months (257 patients completed follow-up)
- Primary endpoint: Composite of myocardial infarction, stroke, or death from any cause
Key findings that establish causality:
- 58.4% of patients (150/257) had polyethylene detected in carotid plaques (mean 21.7 ± 24.5 μg/mg of plaque)
- 12.1% of patients (31/257) had measurable polyvinyl chloride (mean 5.2 ± 2.4 μg/mg of plaque)
- Electron microscopy revealed jagged-edged foreign particles within plaque macrophages
- Hazard ratio of 4.53 (95% CI: 2.00-10.27; P<0.001) for the primary composite endpoint in MNP-positive versus MNP-negative patients
This represents the first direct human evidence linking environmental plastic contamination to major adverse cardiovascular events 1.
Supporting Evidence from Systematic Reviews
Recent Systematic Analyses (2026)
Two comprehensive systematic reviews published in 2026 synthesized the broader evidence base:
The Journal of Xenobiotics systematic review included 14 human studies and found MNPs detected in multiple cardiovascular matrices, with suggested associations to 2:
- Major adverse cardiovascular events
- Acute coronary syndrome and myocardial infarction
- Arterial stenosis and vascular calcification
- Thromboembolic disease
- Hypertension
- Inflammatory and coagulation biomarkers
- Lipid profile abnormalities
Critical limitation: The certainty of evidence was rated as "very low" with most studies having high or very high risk of bias, indicating causality remains unproven despite suggestive associations 2.
The Cardiovascular Toxicology reviews (two separate publications in 2026) corroborated these findings, reporting MNP presence in patients with myocardial infarction, coronary artery disease, and carotid stenosis, with higher MNP levels correlating with inflammatory and coagulation biomarkers 3, 4.
Mechanistic Studies Supporting Biological Plausibility
Real-World Nanoplastic Effects (2026)
The Archives of Toxicology study tested four environmentally relevant nanoplastics on primary human umbilical vein endothelial cells (HUVECs) 5:
Tested materials (all ~200 nm):
- Pristine polystyrene (PS)
- Biodegradable polylactic acid (PLA)
- Polytetrafluoroethylene (PTFE)
- Post-consumer polyethylene terephthalate (PET)
Critical findings showing endothelial dysfunction:
- All nanoplastics were internalized by endothelial cells
- PET-nanoplastics triggered IL-6 secretion and intracellular cholesterol accumulation
- PTFE and PET-nanoplastics significantly impaired cell migration and wound closure
- Irregular, environmentally realistic nanoplastics induced stronger endothelial stress responses than pristine spherical particles
This demonstrates a clear gradient: irregular, real-world nanoplastics cause more severe endothelial dysfunction than laboratory-grade particles 5.
Major Knowledge Gaps and Methodological Limitations
Current research limitations that must be acknowledged 2:
- Lack of standardized detection protocols across studies
- Absence of validated biomarkers for MNP exposure
- No established dose-response relationships
- Insufficient contamination control in many studies
- Limited adjustment for confounding variables
- Heterogeneous analytical methods preventing meta-analysis
The environmental relevance problem: Most historical research used pristine polystyrene microspheres, which poorly represent real-world exposure 6. The 2024 Particle and Fibre Toxicology guidelines emphasize that environmentally relevant nanoplastics (weathered, irregular, polydisperse) are fundamentally different from laboratory models 6.
Clinical Implications
The evidence positions MNPs as an emerging cardiovascular risk factor requiring 4:
- Integration into cardiovascular disease prevention frameworks
- Development of exposure biomarkers for risk stratification
- Consideration of iatrogenic exposure through cardiovascular medical devices
- Environmental health policy interventions
Common pitfall: Assuming all nanoplastics behave identically. The evidence clearly shows particle shape, polymer type, and weathering status dramatically affect biological impact 5.
The bottom line for clinical practice: While the Marfella trial 1 provides the strongest evidence that MNPs in atherosclerotic plaques predict adverse cardiovascular outcomes, the field lacks standardized exposure assessment tools and intervention strategies. Clinicians should be aware of this emerging risk factor, but specific screening or prevention recommendations await further research with standardized methodologies 2, 3.